C-met Overexpression
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects (NCT01892527) | Armando Santoro, MD | 2013-03-01 |
Track C-met Overexpression automatically
Every clearance here is in the API, with alerts when new ones post.